• user warning: Table './fnndrupaldev/term_node' is marked as crashed and last (automatic?) repair failed query: SELECT t.* FROM term_node r INNER JOIN term_data t ON r.tid = t.tid INNER JOIN vocabulary v ON t.vid = v.vid WHERE r.vid = 455404 ORDER BY v.weight, t.weight, t.name in /var/www/www.fnno.com/htdocs/modules/taxonomy/taxonomy.module on line 617.
  • user warning: Table './fnndrupaldev/sessions' is marked as crashed and last (automatic?) repair failed query: SELECT COUNT(sid) AS count FROM sessions WHERE timestamp >= 1416844687 AND uid = 0 in /var/www/www.fnno.com/htdocs/includes/session.inc on line 111.
  • user warning: Table './fnndrupaldev/sessions' is marked as crashed and last (automatic?) repair failed query: SELECT DISTINCT u.uid, u.name, s.timestamp FROM users u INNER JOIN sessions s ON u.uid = s.uid WHERE s.timestamp >= 1416844687 AND s.uid > 0 ORDER BY s.timestamp DESC in /var/www/www.fnno.com/htdocs/modules/user/user.module on line 765.

Analyst Rating Flashback: Illumina Up 6.4% Since Upgraded 7 Days Ago (ILMN)

Published on Fri, 03/08/2013 - 10:11
By Mallory Stone

Illumina was upgraded from Neutral to Buy by UBS one week ago. Illumina shares are selling at $53.33, 6.4% above the $50.13 price point of one week ago.

Illumina share prices have moved between a 52-week high of $79.40 and a 52-week low of $25.57 and are now trading 109% above that low price at $53.47 per share. Over the last five market days, the 200-day moving average (MA) has gone up 0.4% while the 50-day MA has declined 0.2%.

Illumina has overhead space with shares priced $53.47, or 2.3% below the average consensus analyst price target of $54.73. The stock should discover initial support at its 50-day moving average (MA) of $51.64 and subsequent support at its 200-day MA of $46.98.

Illumina, Inc. develops, manufactures and markets integrated systems for the large scale analysis of genetic variation and biological function. The Company provides a comprehensive line of products and services that currently serve the sequencing, genotyping and gene expression markets for genomic research centers, pharmaceutical companies, academic institutions and biotechnology companies.

By Mallory Stone
mstone@fnno.com

Latest News from FNNO

Shares of Medifast Under Pressure, Down ...

Medifast (NYSE:MED) is one of today's biggest movers, down 5.9% to $29.06. The S&P is ...

Stock Investors Bid Up Shares of CardioN...

CardioNet (NASDAQ:BEAT), a company whose shares are moving quickly, is trading 6.8% hig ...

Stock Investors Bid Up Shares of Ariad P...

Ariad Pharmaceuticals (NASDAQ:ARIA) is one of today's notable stocks on the rise, up 10 ...

Buyers Accumulate Shares of Platinum Und...

One of today's stocks on the move is Platinum Underwriters Holdings (NYSE:PTP), up 19.4 ...

Hot Stock: XOMA, Shares Gain 6.0% (XOMA)...

XOMA (NASDAQ:XOMA) is one of today's best performing low-priced stocks, up 6.0% to $4.8 ...

Watch for Shares of Meredith (MDP) to Ap...

Shares of Meredith (NYSE:MDP) have bullishly opened above the pivot of $51.00 today and ...

Next Resistance Level for Public Storage...

Shares of Public Storage (NYSE:PSA) have bullishly opened above the pivot of $185.21 to ...

Watch for Shares of M&T Bank (MTB) to Ap...

Shares of M&T Bank (NYSE:MTB) have bullishly opened above the pivot of $125.06 today an ...